ImmunityBio Shares Surge on Clinical and Commercial Milestones

A convergence of robust clinical data, explosive revenue growth, and a key international regulatory approval has propelled ImmunityBio’s stock to dramatic gains this week. The biopharmaceutical company’s recent announcements have ignited investor enthusiasm, raising the central question of whether this rally is built on a foundation sustainable for the long term.

A Week of Catalysts Drives Investor Interest

The momentum began earlier in the week with the release of preliminary full-year 2025 figures. ImmunityBio reported preliminary net product revenue for its therapy Anktiva of approximately $113 million. This staggering figure represents growth of roughly 700% year-over-year and exceeded analyst expectations, providing the first clear evidence of the drug’s commercial traction—a critical metric for emerging biotech firms.

Shortly thereafter, the company received significant international validation. The Saudi Food and Drug Authority (SFDA) granted approval for Anktiva for use in both bladder cancer and non-small cell lung cancer (NSCLC). This authorization opens a new international market and signals that the therapy’s data package is compelling to regulators beyond the United States. This news followed earlier positive study data for Anktiva in NSCLC released at the start of the week.

Friday’s Clinical Updates Fuel the Rally

The most potent catalysts arrived on Friday, stemming from two separate clinical trial updates.

First, ImmunityBio reported advanced patient recruitment in its pivotal QUILT-2.005 study for Anktiva in non-muscle invasive bladder cancer (NMIBC). Enrollment has now surpassed 85% of the target, exceeding the company’s internal projections. Management now anticipates completing recruitment by the second quarter of 2026, setting the stage for a Biologics License Application (BLA) submission to the U.S. FDA by the end of that year. The probability of securing an additional bladder cancer indication for Anktiva is bolstered by this rapid recruitment and prior robust efficacy data. An earlier FDA-requested interim analysis had already shown that the combination of Anktiva and BCG statistically significantly extended the duration of complete response compared to BCG alone.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Second, the company unveiled encouraging new data for its next-generation CAR-NK cell therapy. In the ongoing QUILT-106 study for patients with Non-Hodgkin Lymphoma, sustained complete remissions have been observed. One patient, notably, maintained a complete response 15 months after therapy concluded. Across the first four treated patients, the company reported a 100% disease control rate. This outpatient, chemotherapy-free treatment approach highlights the potential of a novel and potentially better-tolerated therapeutic pathway.

The market’s reaction to this confluence of news was decisive. Trading volume on Friday skyrocketed to 182 million shares, far above the average of 16 million. The equity closed at $5.52, cementing a weekly gain of over 100% and placing it firmly in positive territory for the year-to-date period.

Key Developments at a Glance:
* Anktiva preliminary 2025 net product revenue of ~$113 million, representing ~700% year-over-year growth.
* SFDA approval for Anktiva in bladder cancer and NSCLC in Saudi Arabia.
* Positive NSCLC clinical data announced earlier in the week.
* QUILT-2.005 trial recruitment surpasses 85% of target, with completion expected by Q2 2026.
* Encouraging QUILT-106 data showing sustained remissions in Non-Hodgkin Lymphoma.
* Share price has more than tripled over the past 30 trading days.

Looking Ahead: Critical 2026 Milestones

The coming months outline several concrete milestones for ImmunityBio. Operationally, the completion of patient recruitment for the QUILT-2.005 study by Q2 2026 is the next major clinical step. Success within this timeline would keep the company on track for its planned BLA submission for an additional Anktiva indication by the end of 2026.

Commercially, the next comprehensive quarterly report—expected around March 2, 2026—will be pivotal. This disclosure should provide detailed insight into the regional and indication-based sales trajectory for Anktiva and indicate whether the exceptional growth pace of 2025 can be at least partially sustained. Recent analyst reports largely categorize the stock with “Strong Buy” or “Moderate Buy” ratings, assessments that will now be tested against the upcoming clinical and financial results.